Mark Kawakami bought $1,442 of RKDA
Chief Financial Officer at Arcadia Biosciences, Inc.. 700 shares at an average of $2.06, traded Aug 1, 2024, filed Aug 20, 2024.
Score components
- +22RoleCFO
- 0Trade size$1k at market
- +10Relative to holdingsHoldings up 55%
- +8Price context37% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.1%, 3m +6.7%, 6m +69.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-099338, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 1, 2024 | POpen-market purchase Common Stock | +700 | $2.06 | $1,442 | 1,981 | Aug 20, 2024 |
Related signals
Other insiders at Arcadia Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | Arcadia Biosciences, Inc. | Thomas J. Schaefer Chief Executive Officer | $1,743 700 shares | +33% | |
| 36Weak | Arcadia Biosciences, Inc. | Mark Kawakami Chief Financial Officer | $1,743 700 shares | +35% | |
| 47Moderate | Arcadia Biosciences, Inc. | Thomas J. Schaefer Chief Executive Officer | $1,442 700 shares | +49% | |
| 50Moderate | RKDAbuy Arcadia Biosciences, Inc. | Thomas J. Schaefer Chief Financial Officer | $1,442 700 shares | +97% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.